PROK Stock — ProKidney Corp. Class A: Cash, EV, Pipeline

Share price

$1.91

Market cap

$577.4M

Cash

$181.6M

Enterprise value

$395.8M

Balance sheet

Cash	$181.6M
Debt	$0.0M
Net cash	$181.6M
Enterprise value	$395.8M
Basic shares	141.9M shares
Fully diluted shares	181.8M shares
Fully diluted market cap	$347.2M
Cash per share	$1.28

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PROK daily closes…

Loading price history…

Pipeline assets

Rilparencel

Phase 3 · Active Modality: autologous selected renal cell therapy

Indications

advanced chronic kidney disease with type 2 diabetes (Phase 3)

Catalysts

— Q2 2027
— H2 2029

Status note REGEN-006 (PROACT 1) Phase 3 ongoing in Stage 4 and late Stage 3b CKD; RMAT designation; enrollment completed for the accelerated approval efficacy analysis.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Renal Autologous Cell Therapy (REACT/ rilparencel)
Lead indication	Type 2 Diabetes Mellitus
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05099770	Phase 3	Active, not recruiting	Sponsor	Prokidney	—	Type 2 Diabetes Mellitus; Chronic Kidney Diseases	—
NCT05918523	Not disclosed	Recruiting	Sponsor	Prokidney	—	Diabetic Kidney Disease; Chronic Kidney Diseases	—
NCT06790498	Not disclosed	Enrolling by invitation	Sponsor	Prokidney	—	Diabetic Kidney Disease; Chronic Kidney Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Prokidney on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PROK — ProKidney Corp. Class A

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials